Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/19855
Title: | Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer | Authors: | Pujol, Jean-Louis Vansteenkiste, Johan F. De Pas, Tommaso Martino Atanackovic, Djordje Reck, Martin THOMEER, Michiel Douillard, Jean-Yves Fasola, Gianpiero Potter, Vanessa Taylor, Paul Bosquee, Lionel Scheubel, Robert Jarnjak, Silvija Debois, Muriel Alves, Pedro de Sousa Louahed, Jamila Brichard, Vincent G. Lehmann, Frederic F. |
Issue Date: | 2015 | Publisher: | LIPPINCOTT WILLIAMS & WILKINS | Source: | JOURNAL OF THORACIC ONCOLOGY, 10 (10), p. 1458-1467 | Abstract: | Introduction: To assess the safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with stage IB-III MAGE-A3-positive non-small-cell lung cancer (NSCLC) who were or were not undergoing standard cisplatin/vinorelbine chemotherapy. Methods: This open, prospective, multicenter, parallel-group phase I study (NCT00455572) enrolled patients with resected (cohorts 1-3) or unresectable (cohort 4) MAGE-A3-positive NSCLC. MAGE-A3 immunotherapeutic (300 g recombinant MAGE-A3 formulated with AS15) was administered (eight doses, 3 weeks apart) concurrent with (cohort 1), after (cohort 2), or without (cohort 3) standard-adjuvant chemotherapy, or after standard radiotherapy and/or chemotherapy (cohort 4). Results: Sixty-seven patients received greater than or equal to 1 dose of MAGE-A3 immunotherapeutic. Grade 3/4 adverse events (AEs) were reported for 16 out of 19 (84%), 2 out of 18 (11%), 5 out of 18 (28%), and 1 out of 12 (8%) patients in cohorts 1, 2, 3, and 4, respectively. Many grade 3/4 AEs in cohort 1 (e.g., neutropenia) were typical of chemotherapy. Six patients, including three in cohort 1, reported study treatment-related grade 3/4 AEs (injection-site reactions or musculoskeletal/back pain, which resolved within 5 days). One patient (in cohort 4) died, but this and the other serious adverse events were not study treatment related. MAGE-A3-specific antibody responses to immunotherapy were induced in all patients evaluated in all cohorts. MAGE-A3-specific CD4(+) T-cell responses to immunotherapy were detected in 4 out of 11 (36%), 4 out of 15 (27%), 2 out of 8 (25%), and 5 out of 6 (83%) evaluated patients in cohorts 1, 2, 3, and 4, respectively; and CD8(+) T-cell responses were only detected in four patients. Conclusion: In resected and unresectable NSCLC patients and irrespective of whether standard chemotherapy was concurrent or not, MAGE-A3 immunotherapeutic is well tolerated and induces MAGE-A3-specific immune responses. | Notes: | [Pujol, Jean-Louis] CHRU Montpellier, Thorac Oncol Unit, Arnaud de Villeneuve Hosp, F-34295 Montpellier, France. [Vansteenkiste, Johan F.] Katholieke Univ Leuven, Univ Hosp, Dept Pneumol, Leuven, Belgium. [De Pas, Tommaso Martino] European Inst Oncol, Med Oncol, Milan, Italy. [Atanackovic, Djordje] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA. [Reck, Martin] Hosp Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany. [Thomeer, Michiel] Ziekenhuis Oost Limburg, Dept Resp Med, Genk, Belgium. [Thomeer, Michiel] Univ Hasselt, LCRP Oncol Cluster, Hasselt, Belgium. [Douillard, Jean-Yves] ICO R Gauducheau, Dept Med Oncol, St Herblain, France. [Fasola, Gianpiero] Univ Hosp S Maria della Misericordia, Dept Oncol, Udine, Italy. [Potter, Vanessa] Nottingham Univ Hosp NHS Trust, Nottingham, England. [Taylor, Paul] Univ S Manchester Hosp, Northwest Lung Ctr, Manchester M20 8LR, Lancs, England. [Bosquee, Lionel] Andre Renard Clin, Thorac Oncol Pneumol Serv, Herstal, Belgium. [Scheubel, Robert] Waldburg Zeil Clin, Clin Thorac Surg, Wangen Im Allgau, Germany. [Jarnjak, Silvija; Debois, Muriel; Alves, Pedro de Sousa; Louahed, Jamila; Brichard, Vincent G.; Lehmann, Frederic F.] GSK Vaccines, Rixensart, Belgium. | Keywords: | adjuvant chemotherapy; immunotherapy; immunostimulant; MAGE-A3; non–small cell lung carcinoma; vaccine;Adjuvant chemotherapy; Immunotherapy; Immunostimulant; MAGE-A3; Non-small cell lung carcinoma; Vaccine | Document URI: | http://hdl.handle.net/1942/19855 | ISSN: | 1556-0864 | e-ISSN: | 1556-1380 | DOI: | 10.1097/JTO.0000000000000653 | ISI #: | 000361719200010 | Rights: | Copyright © 2015 by the International Association for the Study of Lung Cancer | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2016 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S1556086415335218-main.pdf Restricted Access | 1.13 MB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
34
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
47
checked on Apr 22, 2024
Page view(s)
56
checked on Sep 7, 2022
Download(s)
46
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.